Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.47 |
| ▸ | SCN1A | P35498 | 1/20 | 0.47 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | PPIA | P62937 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 4/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL714461 | 0.92 | LMNA (0.57) | MEN1KMT2ALMNASMN1; SMN2SCN8A | |
| SCHEMBL3742455 | 0.86 | NAMPT (0.54) | NAMPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL713897 | 0.81 | MEN1 (0.54) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL710057 | 0.78 | SMN1; SMN2 (0.60) | MEN1KMT2ALMNASMN1; SMN2PPIA | |
| SCHEMBL712299 | 0.78 | SCN9A (0.68) | MEN1KMT2ASMN1; SMN2ALDH1A1SCN8A | |
| SCHEMBL712534 | 0.73 | SCN9A (0.54) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL712892 | 0.72 | SCN9A (0.63) | MEN1KMT2ALMNASMN1; SMN2SCN5A | |
| SCHEMBL714602 | 0.72 | KMT2A (0.53) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL713144 | 0.72 | SCN9A (0.53) | MEN1KMT2ALMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL713743 | 0.71 | KMT2A (0.52) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124610-B2 | Sodium channel inhibitors | ICAGEN INC. (US) | 2012-02-28 | — | — | US | claimed |
| US-8124610-B2 | Sodium channel inhibitors | ICAGEN INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | ICAGEN (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023740-A1 | SODIUM CHANNEL INHIBITORS | TRPV1, SCN1A, SCN2A | NAMPT 687/4885MEN1 4426/4885KMT2A 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.